BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30567630)

  • 1. Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics.
    Kim WH; Kim HJ; Park HY; Park JY; Chae YS; Lee SM; Cho SH; Shin KM; Lee SY
    Ultrasound Med Biol; 2019 Mar; 45(3):702-709. PubMed ID: 30567630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
    Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
    Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
    Wang L; Li Y; Li J; Wang T; Xie Y; He Y; Fan Z; Ouyang T
    Clin Transl Oncol; 2021 Feb; 23(2):240-245. PubMed ID: 32519177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Le-Petross HT; McCall LM; Hunt KK; Mittendorf EA; Ahrendt GM; Wilke LG; Ballman KV; Boughey JC
    AJR Am J Roentgenol; 2018 Mar; 210(3):669-676. PubMed ID: 29381381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study.
    Huang X; Shi Z; Mai J; Liu C; Liu C; Chen S; Lu H; Li Y; He B; Li J; Cun H; Han C; Chen X; Liang C; Liu Z
    Acad Radiol; 2023 Jul; 30(7):1257-1269. PubMed ID: 36280517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restaging the axilla after neo-adjuvant chemotherapy for breast cancer: Predictive factors for residual metastatic lymph node disease with negative imaging findings.
    Jung N; Kim HJ; Jung JH; Lee SW; Chae YS; Cheon H; Lee SM; Kim WH
    Breast J; 2019 Mar; 25(2):196-201. PubMed ID: 30714256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer.
    Oruwari JU; Chung MA; Koelliker S; Steinhoff MM; Cady B
    Am J Surg; 2002 Oct; 184(4):307-9. PubMed ID: 12383889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.
    Han X; Jin S; Yang H; Zhang J; Huang Z; Han J; He C; Guo H; Yang Y; Shan M; Zhang G
    Br J Radiol; 2021 Sep; 94(1125):20210520. PubMed ID: 34415197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer.
    Huang JX; Lin SY; Ou Y; Shi CG; Zhong Y; Wei MJ; Pei XQ
    Eur Radiol; 2022 Sep; 32(9):5986-5996. PubMed ID: 35364714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.
    Schipper RJ; Moossdorff M; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2015 Jan; 84(1):41-47. PubMed ID: 25458227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer.
    Ha SM; Cha JH; Kim HH; Shin HJ; Chae EY; Choi WJ
    Acta Radiol; 2017 Oct; 58(10):1198-1205. PubMed ID: 28350255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined conventional ultrasonography with clinicopathological features to predict axillary status after neoadjuvant therapy for breast cancer: A case-control study.
    Yan Y; Jiang T; Sui L; Ou D; Qu Y; Chen C; Lai M; Ni C; Liu Y; Wang Y; Xu D
    Br J Radiol; 2023 Dec; 96(1152):20230370. PubMed ID: 37750854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
    Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
    J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.